T T Dunston1, M A Khomutov2, S B Gabelli1,3,4, T M Stewart1, J R Foley1, S N Kochetkov2, A R Khomutov2, R A Casero1. 1. Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA. 2. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia. 3. Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 4. Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Abstract
Homeostasis of the biogenic polyamines spermine (Spm) and spermidine (Spd), present in μM-mM concentrations in all eukaryotic cells, is precisely regulated by coordinated activities of the enzymes of polyamine synthesis, degradation, and transport, in order to sustain normal cell growth and viability. Spermine oxidase (SMOX) is the key and most recently discovered enzyme of polyamine metabolism that plays an essential role in regulating polyamine homeostasis by catalyzing the back-conversion of Spm to Spd. The development of many types of epithelial cancer is associated with inflammation, and disease-related inflammatory stimuli induce SMOX. MDL72527 is widely used in vitro and in vivo as an irreversible inhibitor of SMOX, but it is also potent towards N1-acetylpolyamine oxidase. Although SMOX has high substrate specificity, Spm analogues have not been systematically studied as enzyme inhibitors. Here we demonstrate that 1,12-diamino-2,11-bis(methylidene)-4,9-diazadodecane (2,11-Met2-Spm) has, under standard assay conditions, an IC50 value of 169 μM towards SMOX and is an interesting instrument and lead compound for studying polyamine catabolism. Copyright ® 2020 National Research University Higher School of Economics.
Homeostasis of the biogenic polyaminesn class="Chemical">spermine (Spm) and spermidine (Spd), present in μM-mM concentrations in all eukaryotic cells, is precisely regulated by coordinated activities of the enzymes of polyamine synthesis, degradation, and transport, in order to sustain normal cell growth and viability. Spermine oxidase (SMOX) is the key and most recently discovered enzyme of polyamine metabolism that plays an essential role in regulating polyamine homeostasis by catalyzing the back-conversion of Spm to Spd. The development of many types of epithelial cancer is associated with inflammation, and disease-related inflammatory stimuli induce SMOX. MDL72527 is widely used in vitro and in vivo as an irreversible inhibitor of SMOX, but it is also potent towards N1-acetylpolyamine oxidase. Although SMOX has high substrate specificity, Spm analogues have not been systematically studied as enzyme inhibitors. Here we demonstrate that 1,12-diamino-2,11-bis(methylidene)-4,9-diazadodecane (2,11-Met2-Spm) has, under standard assay conditions, an IC50 value of 169 μM towards SMOX and is an interesting instrument and lead compound for studying polyamine catabolism. Copyright ® 2020 National Research University Higher School of Economics.
The biogenic polyaminesn class="Chemical">spermine (Spm) and spermidine (Spd), and their diamine
precursor putrescine (Put), are organic polycations present in all eukaryotic
cells in μM-mM concentrations that a priori determine the
diversity of their functions, many of which are vitally important [1, 2].
Polyamine intracellular levels are strictly controlled by precise regulation of
the activity, biosynthesis and degradation of key enzymes of their metabolism.
Polyamines are tightly involved in these regulatory processes, and the cell
spends considerable energy to maintain polyamine homeostasis [3]. Disturbances of polyamine metabolism and
homeostasis are associated with many diseases [1-6], but they may be
most essential to cancer cells, which can have elevated requirements for
polyamines. Compounds capable of specifically decreasing the polyamine pool
have potential as anticancer drugs [5]
and for chemoprevention [6].
FAD-dependent n class="Gene">spermine oxidase
(SMOX, Fig. 1)
converts Spm to Spd with the formation of hydrogen peroxide, a source of ROS,
and 3-aminopropanal, which can spontaneously form highly toxic acrolein
(Fig. 1). SMOX has been demonstrated
to contribute to cancer, including prostate, colon and gastric cancer induced
by infection and inflammation [7, 8, 9]. In
gastric cancer, Helicobacter pyloriinfection induces SMOX in gastric
epithelial cells that results in the generation of hydrogen peroxide and
acrolein-producing 3-aminopropanal; these lead to DNA damage and apoptosis
[10]. Inhibition of SMOX with the
N1-acetylpolyamine oxidase
(PAOX, Fig. 1)
irreversible inhibitor MDL72527
{N1,N4-(bis(2,3-butadienyl)-1,4-butanediamine)} [11], which has an IC50 value of 90 μM towards
SMOX, reduces these effects [8, 9]. However, in some cases it is necessary to
discriminate the individual impact of SMOX and PAOX in an integral biological
effect or development of the disease and MDL72527, which has been successfully
and widely used for decades and inhibits both enzymes. Specific, effective and
irreversible inhibitors of SMOX are lacking, partly because the X-ray structure
of the enzyme is not available. The analysis of structure/activity
relationships of polyamine analogues for PAOX and SMOX has indicated that both
enzymes recognize two positively charged amino groups and have hydrophobic
pocket(s) located close to the substrate binding site [12]. Therefore, a number of N-substituted diamines were
investigated as potential inhibitors of SMOX. However, the problem of specific
inhibition of each enzyme has still not been completely solved.
Polyamine interconversions. dcAdoMet – decarboxylated
S-adenosylmethionine; MTA – 5’-deoxy-5’-
methylthioadenosine; n class="Gene">PAOX – N1-acetylpolyamine oxidase;
SMOX – spermine oxidase; SpdSy – spermidine synthase; SpmSy –
spermine synthase; SSAT – spermidine/spermine-
N1-acetyltransferase
C9-4 (n class="Chemical">N1-nonyl-1,4-diaminobutane) is a Put derivative having
an IC50 value of 2.6 μM towards PAOX and an IC50
value of 88 μM towards SMOX. This compound reduced the volume of brain
infarction in a mouse model more effectively than MDL72527 [13]. The nor-Spd derivative
SI-4650 (N-(3-{[3-(dimethylamino)
propyl]amino}propyl)-8-quinolinecarboxamide) has an IC50 value of
380 μM towards SMOX and an IC50 value of 35 μM towards
PAOX. SI-4650 inhibited cell growth, induced apoptosis, and promoted autophagy,
making it a compound of interest for cancer treatment [12]. Recently, among a family of
N-substituted 3,5-diamino-1,2,4-triazoles, an efficient and
specific inhibitor of SMOX,
N5-(2-([1,1′-biphenyl]-4-yloxy)
benzyl)-1H-1,2,4-triazole-3,5-diamine, was identified as
having an IC50 value of 25 μM (the compound had an
IC50 value of >200 μM towards PAOX); this compound
efficiently inhibited SMOX in cell culture [14]. Currently, this is the one compound that is significantly
more effective towards SMOX than PAOX. Moreover, this
N-substituted 3,5-diamino-1,2,4-triazole is 3.5-fold more
potent against SMOX in vitro if compared with MDL72527 and is
a promising tool to study the effects of specific SMOX inhibition on polyamine
metabolism [14].
(A) Possible mechanism of SMOX inhibition with n class="Chemical">2,11-Met2-Spm.
(B) Structures of bis-methylated Spm
analogues: 1,12-Me2Spm, 2,11-Me2Spm and 3,10-Me2SpmProperly designed Spm derivatives/analogues have never been widely studied as
specific inhibitors of n class="Gene">SMOX. However, taking into consideration that Spm is a
substrate of SMOX and not a substrate of PAOX, one may expect that Spm
derivatives may be a useful source of specific SMOX inhibitors. In the present
paper, we started such investigations using 2,11-Met2-Spm
()
for the inhibition of SMOX.
EXPERIMENTAL
Materials1,12-Diamino-2,11-bis(methylidene)-4,9-diazadodecane tetrahydrochloride
(n class="Chemical">2,11-Met2-Spm) was synthesized essentially as described in [15] starting from
2-chloromethyl-3-chloropropene-1 (Aldrich), which was reacted with potassium
phthalimide to give 1-phthalimido-2-methylidene-3-chloropropane, which was used
to alkylate bis-N1,N4-2-nitrophenylsulfonyl-
1,4-diaminobutane. Subsequent removal of protecting groups resulted in
2,11-Met2-Spm in a good overall yield.
Protein expression and purificationThe bacterial expression vector pET15b carrying the gene coding for the humann class="Gene">SMOX protein was used to transform and express SMOX in E. coli
BL21(DE3) competent cells using Luria Broth (LB) media supplemented
with carbenicillin (100 μg/mL), 20 mg/L riboflavin and induced with 0.1 mM
IPTG overnight at 18°C. The cells were lysed in a buffer containing 50 mM
Na2HPO4/NaH2PO4 (pH 8.0), 150 mM
NaCl, 10 mM imidazole, 10% glycerol, and 1% Triton X-100. Flavin adenine
dinucleotide (FAD) was added at 250 μM with protease inhibitor (1 mM
phenylmethylsulfonyl fluoride) and 7 μL β-mercaptoethanol per 10 mL
lysis buffer. The lysate was centrifuged at 12,000 rpm for 30 min at 4°C,
and the supernatant was applied to a Ni-NTA column. The column was
pre-equilibrated with lysis buffer, and the protein was eluted in a gradient in
buffer containing 50 mM
Na2HPO4/NaH2PO4 (pH 8.0), 150 mM
NaCl, and imidazole ranging from 50 to 250 mM. To remove the polyhistidine tag,
the protein was subjected to thrombin cleavage (25 U) and dialyzed with 10K
MWCO snakeskin into buffer containing 100 mM Tris-HCl (pH 7.5) and 50 mM NaCl
(with BME) overnight at 4°C. The resulting protein solution was then
subjected to Source15Q anion exchange to remove impurities.
SMOX activity assay and enzyme inhibition studiesSMOX activity was measured using a chemiluminescent enzyme-based assay
detecting the formation of n class="Chemical">H2O2 in the presence of Spm as
the substrate, as described earlier [16]. To measure the activity of 2,11-Met2-Spm against SMOX,
the enzyme (300 ng) in 0.083 M glycine buffer (pH 8.0) and the inhibitor
(0–250 μM) were added to the luminol-HRP master mix and incubated at
37°C for 2 min. Spm was then added to the reaction mixture at a final
concentration of 250 μM, vortexed for 3 s, and chemiluminescence was
integrated over 40 s. Data were averaged and normalized to the blank reaction
(no inhibitor) as % SMOX activity. Inactivated SMOX served as a negative
control and was accounted for in the calculations.
RESULTS AND DISCUSSION
Design of a SMOX inhibitor of n class="Chemical">Spm origin
There is a set of different strategies to design suicide inhibitors of the
enzymes of amino acid metabolism. One strategy consists in using a
substrate/product analogue with a properly positioned activated double bond(s);
for example, the allene group inn class="Chemical">MDL72527, which obeys irreversible inhibition
[10]. An activated double bond may be
generated at one of the steps of the substrate-like transformation of the
inhibitor, like in the case of pyridoxal-5’-phosphate (PLP)-dependent
ornithine decarboxylase and its suicide inhibitor DFMO [17]. The subsequent addition of a nucleophile to the activated
double bond results in irreversible inhibition, which is developed in time. A
double bond may already exist in the structure of the amino acid analogue and
become activated as a result of the interaction with the coenzyme, similar to
the mechanisms involved with the interaction between α-vinylic amino acids
and PLP-dependent enzymes [18]. Here,
these considerations were transformed into
1,12-diamino-2,11-bis(methylidene)-4,9-diazadodecane tetrahydrochloride
(2,11-Met2-Spm) having a double bond in the beta position to the splitting
C-N bond
().
The methylidene group may
be activated as a result of the substrate-like transformation of 2,11-Met2-Spm,
leading to the formation of the intermediate Schiff base
().
The possibility of substrate-like transformations of
2,11-Met2-Spm is evidenced by the known dependence of the substrate properties
of bis-methylated Spm analogues in the SMOX reaction on the
position of the methyl groups in the analogue structure. The ability of racemic
1,12-Me2Spm, 2,11-Me2Spm and 3,10-Me2Spm
()
to serve as substrates for SMOX decreased as the methyl group was positioned
closer to the secondary (N4) amino group, and for 3,10-Me2Spm, kinetic parameters
were impossible to determine [19]. This is
likely because the methyl group at the third position of the Spm backbone may
restrict the proton splitting at the C3 carbon atom and influence the formation
of the Shiff base, a key intermediate of the SMOX reaction.
Enzyme inhibition studiesThe experiments on the inhibition of SMOX with n class="Chemical">2,11-Met2-Spm were performed
under standard assay conditions, preincubating the enzyme with the inhibitor
for 2 min and starting the reaction with the addition of Spm: with 250 μM
of 2,11-Met2-Spm added, the enzyme was inhibited by 72%
().
If the inhibition is competitive, the affinity of 2,11-Met2-Spm
towards SMOX must be greater than that of Spm (Spm concentration in the
substrate mixture was also 250 μM, i.e. 14 Km). High affinity of
2,11-Met2-Spm for SMOX seems unlikely due to the high substrate specificity of
the enzyme. Among twenty-nine closely related Spm analogues of tetra- and
pentaamine nature, the best substrate was pentaamine 3433
(1,16-diamino-4,8,13-triazahexadecane), with Km of 1.3 μM, i.e. 14 times
better than Spm; among the rest, only pentaamine 3434
(1,17-diamino-4,9,13-triazaheptadecane) was as efficient as Spm
[20]. However, if the inhibition of SMOX is
irreversible, the affinity of the inhibitor towards the enzyme at the
reversible stage may be poor, being consistent with the results observed when
SMOX was preincubated with 2,11-Met2-Spm at 100 μM and the enzyme activity
was inhibited only by 33%
().
It is currently unclear
how quickly inhibition develops in time and the 2 min preincubation time,
typical for MDL72527, may be too short for 2,11-Met2-Spm and SMOX because of
the steric effect of the methylidene group in the β-position to the
splitting C-N bond.
Inhibition of SMOX with n class="Chemical">2,11-Met2-Spm (blue line) and MDL72527 (yellow line) as
a positive control. Conditions: HRP-luminol (1 ng) in glycine buffer pH 8.0,
enzyme and inhibitor (0–250 μM) were incubated at 37°C for 2
min. Spm was then added at a final concentration of 250 μM, and
luminescence was integrated for 40 s. 2,11-Met2-Spm and MDL72527 have
IC50 values of 169 and 100 μM, respectively. Unlike
2,11-Met2-Spm, the inhibition of purified SMOX by MDL72527 does not conform
well to a linear transformation but it correlates well with the published
IC50 value of 90 μM [14]. The R-squared values for
2,11-Met2-Spm an MDl72527 are 0.992 and 0.7821, respectively. Data were
collected from three independent experiments with standard deviations (SD)
The activity of 2,11-Met2-Spm towards n class="Gene">SMOX (IC50 = 169 μM) was
worse than that reported for MDL72527 (IC50 = 90 μM [14]), which is an irreversible PAOX inhibitor
of a Put nature with reactive allene substituents. As a Spm derivative, it is
likely that 2,11-Met2-Spm will be less inhibitory of PAOX (natural substrates
are N1-Ac-Spd and less effective N1-Ac-Spm)
compared with SMOX. This is likely based on the comparison of the activity of
the structurally similar rac-2,11-Me2Spm
()
towards SMOX and PAOX. Rac-2,11-Me2Spm was a
comparatively poor substrate of SMOX, having a Vmax of 124 pmol/min/μg
protein and a Km of 121 μM, while the activity of PAOX was inhibited for
60% only at the 500 μM concentration, when a fixed 50 μM
concentration of the substrate N1-Ac-Spd was used in the PAOX
assay [19].
Our results clearly show that it is possible to design a Spm analogue that
inhibits the n class="Chemical">FAD-dependent SMOX, a key enzyme of polyamine catabolism.
2,11-Met2-Spm has an IC50 value of 166 μM towards SMOX.
Although the precise mechanism of the inhibition, the specificity of
2,11-Met2-Spm action, and the activity in cell culture are under investigation,
the development of a selective inhibitor remains critical, not only as an
experimental tool, but also as a potential therapeutic agent as SMOX is known
to play a critical role in the development of multiple diseases, including
cancer [5, 7, 8, 10].
Authors: Rupesh Chaturvedi; Mohammad Asim; Judith Romero-Gallo; Daniel P Barry; Svea Hoge; Thibaut de Sablet; Alberto G Delgado; Lydia E Wroblewski; M Blanca Piazuelo; Fang Yan; Dawn A Israel; Robert A Casero; Pelayo Correa; Alain P Gobert; D Brent Polk; Richard M Peek; Keith T Wilson Journal: Gastroenterology Date: 2011-08-10 Impact factor: 22.682
Authors: Steven Holshouser; Matthew Dunworth; Tracy Murray-Stewart; Yuri K Peterson; Pieter Burger; Joy Kirkpatrick; Huan-Huan Chen; Robert A Casero; Patrick M Woster Journal: Medchemcomm Date: 2019-02-08 Impact factor: 3.597
Authors: Andrew C Goodwin; Christina E Destefano Shields; Shaoguang Wu; David L Huso; XinQun Wu; Tracy R Murray-Stewart; Amy Hacker-Prietz; Shervin Rabizadeh; Patrick M Woster; Cynthia L Sears; Robert A Casero Journal: Proc Natl Acad Sci U S A Date: 2011-08-29 Impact factor: 11.205
Authors: Andrew C Goodwin; Sana Jadallah; Antoun Toubaji; Kristen Lecksell; Jessica L Hicks; Jeanne Kowalski; G Steven Bova; Angelo M De Marzo; George J Netto; Robert A Casero Journal: Prostate Date: 2008-05-15 Impact factor: 4.104
Authors: Johanna C Sierra; M Blanca Piazuelo; Paula B Luis; Daniel P Barry; Margaret M Allaman; Mohammad Asim; Thomas A Sebrell; Jordan L Finley; Kristie L Rose; Salisha Hill; Steven L Holshouser; Robert A Casero; John L Cleveland; Patrick M Woster; Kevin L Schey; Diane Bimczok; Claus Schneider; Alain P Gobert; Keith T Wilson Journal: Oncogene Date: 2020-04-29 Impact factor: 9.867
Authors: Diptesh Sil; Sudipta Panja; Chinmay M Jogdeo; Raj Kumar; Ao Yu; Cassandra E Holbert; Ling Ding; Jackson R Foley; Tracy Murray Stewart; Robert A Casero; David Oupický Journal: Molecules Date: 2022-04-10 Impact factor: 4.927
Authors: Amelia B Furbish; Ahmed S Alford; Pieter Burger; Yuri K Peterson; Tracy Murray-Stewart; Robert A Casero; Patrick M Woster Journal: Med Sci (Basel) Date: 2022-08-30